Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
China Pharma Holdings Inc (CPHI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: CPHI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -82.7% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.96M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) - | Beta 0.75 | 52 Weeks Range 1.20 - 3.35 | Updated Date 06/29/2025 |
52 Weeks Range 1.20 - 3.35 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -106.3% | Operating Margin (TTM) -66.76% |
Management Effectiveness
Return on Assets (TTM) -18.22% | Return on Equity (TTM) -59.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9050107 | Price to Sales(TTM) 1.39 |
Enterprise Value 9050107 | Price to Sales(TTM) 1.39 | ||
Enterprise Value to Revenue 2.11 | Enterprise Value to EBITDA -225.89 | Shares Outstanding 3262000 | Shares Floating 2640623 |
Shares Outstanding 3262000 | Shares Floating 2640623 | ||
Percent Insiders 30.26 | Percent Institutions 1.04 |
Upturn AI SWOT
China Pharma Holdings Inc
Company Overview
History and Background
China Pharma Holdings, Inc. was founded in 1993 and is headquartered in China. It develops, manufactures, and markets pharmaceutical products.
Core Business Areas
- Pharmaceutical Manufacturing: Production of generic drugs, including injectables, tablets, capsules, and oral solutions.
- Distribution and Marketing: Sale and distribution of pharmaceutical products through a network of distributors, hospitals, and pharmacies in China.
Leadership and Structure
The leadership team consists of executives with experience in pharmaceutical manufacturing, sales, and finance. The organizational structure is hierarchical, with various departments overseeing different aspects of the business.
Top Products and Market Share
Key Offerings
- Cardiovascular Drugs: Medications for treating heart conditions. Market share data is not available in public. Competitors include Sanofi, Novartis, and local Chinese companies.
- Central Nervous System Drugs: Medications for neurological disorders. Market share data is not available in public. Competitors include Pfizer, Eli Lilly, and local Chinese companies.
- Oncology Drugs: Medications for cancer treatment. Market share data is not available in public. Competitors include Roche, Merck, and local Chinese companies.
Market Dynamics
Industry Overview
The Chinese pharmaceutical industry is experiencing rapid growth, driven by an aging population, increasing healthcare expenditure, and rising demand for quality drugs.
Positioning
China Pharma Holdings Inc is a player in the generic pharmaceutical market in China. Its competitive advantage lies in its established manufacturing capabilities and distribution network.
Total Addressable Market (TAM)
The TAM for pharmaceuticals in China is expected to reach hundreds of billions of USD. China Pharma Holdings Inc is positioned to capture a portion of this market through its product offerings and distribution channels.
Upturn SWOT Analysis
Strengths
- Established manufacturing facilities
- Extensive distribution network in China
- Portfolio of generic drugs
- Experience in the Chinese pharmaceutical market
Weaknesses
- Reliance on generic drugs
- Limited R&D capabilities
- Exposure to regulatory changes in China
- Smaller scale compared to larger multinational competitors
Opportunities
- Expanding into new therapeutic areas
- Increasing penetration in rural markets
- Developing strategic partnerships
- Acquiring smaller pharmaceutical companies
Threats
- Increasing competition from local and international players
- Price pressure from government regulations
- Counterfeit drugs
- Changes in healthcare policies
Competitors and Market Share
Key Competitors
- Sanofi (SNY)
- Novartis (NVS)
- Pfizer (PFE)
- Eli Lilly and Company (LLY)
- Roche Holding AG (RHHBY)
- Merck & Co., Inc. (MRK)
Competitive Landscape
China Pharma Holdings Inc faces intense competition from both domestic and international pharmaceutical companies. Its smaller size and focus on generic drugs make it more vulnerable to price pressure and regulatory changes.
Growth Trajectory and Initiatives
Historical Growth: Information on historical growth is not publicly available.
Future Projections: Analyst estimates for future growth are not readily available.
Recent Initiatives: Information on recent strategic initiatives is not publicly available in detail.
Summary
China Pharma Holdings Inc is a small player in the competitive Chinese pharmaceutical market, with established manufacturing and distribution but facing challenges from larger companies and regulatory pressures. It needs to expand into new therapeutic areas and enhance its R&D capabilities to achieve sustainable growth. Monitoring regulatory changes and managing competition are crucial for its future success. The company's financial performance remains opaque due to lack of recent, detailed financial data.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Market Research Reports
- SEC Filings (limited available current detail)
Disclaimers:
The analysis is based on limited publicly available information. Market share and financial data are estimates. The information provided is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About China Pharma Holdings Inc
Exchange NYSE MKT | Headquaters - | ||
IPO Launch date 2002-04-17 | President, CEO, Chairman & Interim CFO Ms. Zhilin Li | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 224 | |
Full time employees 224 | |||
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets. It offers Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.